RCS - Deepverge PLC - Notice of Final Results and Annual Report

DeepvergeAnnouncement

13/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220613:nRSM5391Oa&default-theme=true

RNS Number : 5391O  Deepverge PLC  13 June 2022

 

 

 

13 June 2022

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

Notice of Final Results and Annual Report

 

Skin Trust Club continues to expand with accelerated momentum

 

 

DeepVerge (LSE:DVRG.L) today announces that it will publish its Final Results
and Annual Report for the year ended 31 December 2021 on 23 June 2022.

 

Gerard Brandon, CEO of DeepVerge, comments:

"As we prepare to publish our Annual Report demonstrating growth across the
whole business, Skin Trust Club has rapidly become a key segment of the
Labskin Division.  We continue to see accelerated growth with the number of
repeat customers; countries in which we are now operating; additional skincare
brands on our marketplace app plus numerous high-profile companies from
different industry sectors wanting to work with us. In a $145 billion skincare
market, Skin Trust Club is the new era of personalised skin care."

 

Skin Trust Club:

 

Having recently been awarded the Best New Disruptor Brand 2022 from the Pure
Beauty Global Awards, and concluding a study showing more than 63% of people
get their skin type wrong, Skin Trust Club is helping thousands of members get
it right.

 

Skin Trust Club has the largest skin microbiome database in the world and the
range of applications is expanding:

▪       Skin Trust Club B2C:  Member home test kit.

▪       Skin Trust Club B2B:  Test kit sales and data intelligence to
our retail partners through an affiliate programme.

▪       Skin Trust Club B2B: Affiliate programme sales.

▪       Skin Trust Medical B2B:  Home test kit referral services for
dermatology professionals in development.

●      Skin Trust Club has over 20,000 members with more than 50,000
visits per month.

●      The marketplace service is expanding rapidly with more than 300
products now available.

●      Intense interest from the US market resulted in unprecedented
demand for Skin Trust Club test kits.

 

For further information please contact:

 

 DeepVerge plc                                   Gerard Brandon, CEO         +44 (0) 7340 055 648
 SPARK Advisory Partners Limited                 Neil Baldwin/Andrew Emmott  +44 (0) 113 370 8974

 (Nominated Adviser)
 Turner Pope Investments (TPI) Limited (Broker)  Andy Thacker/James Pope     +44 (0) 20 3657 0050

 

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that
develops and applies AI and IoT technology to analytical instruments for the
analysis and identification of bacteria, virus and toxins. Utilising
artificial intelligent data analytics to scientifically prove the impact of
skincare product claims on skin microbiome for most of the top 20 global
cosmetic company clients and remotely detect and identify in real-time,
dangerous pathogens in wastewater treatment plants, drinking water, rivers,
lakes and reservoirs.

 

Skin Trust Club

Skin Trust Club incorporates an artificial intelligence Skincare App and Home
Test Kit that provide simple, at-home skin microbiome testing for personalised
skincare and skin health tracking. The self-administered skin swab is a remote
trial and allows the participant to conduct each stage of the trial without
interaction. Skin Trust Club's DNA Test generates a report that consumers can
use to manage their custom skincare regime. Analysis of skin attributes
provides information to create hundreds of different product combinations to
suit a person's unique skin microbiome.

 

Labskin (Life Science Division)

Labskin is a 3D human skin equivalent test platform that scientifically proves
the impact of skincare product claims in healthcare, life sciences, skin
microbiome clinical trials, pharmaceutical and cosmetics industries. Labskin
have been pioneering the development of a laboratory grown human skin platform
for 15 years and is the only commercially available lab-grown full thickness
human skin model that naturally mimics the skins' microbiome. Labskin's
virtual clinical trials with remote collection of human volunteers' skin
microbiome provides a solution for the collection of volunteer microbiomes to
allow for lab-controlled trials of advanced skin models and human microbiomes.
As the data bank of remote volunteers grows, the higher the accuracy and
increased reliability of virtual product testing that can be provided to
clients, eliminating early human trial and error testing and resulting in a
faster time to market. The Labskin test platform and protocols help clients
maintain an optimum real-world environment, when testing their new ingredients
and existing products, that shows the positive or negative impact on skin's
natural microflora.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFIRRTIILIF